Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2019 | 12-2018 | 09-2018 | 06-2018 | 03-2018 | |
| Sales | 3,000 | 0 | 0 | 0 | 0 |
| Cost of Goods | 100 | N/A | N/A | N/A | N/A |
| Gross Profit | 2,900 | N/A | N/A | N/A | N/A |
| Operating Expenses | 6,806 | 11,146 | 11,358 | 11,438 | 8,407 |
| Operating Income | -3,806 | -11,146 | -11,358 | -11,438 | -8,407 |
| Interest Expense | 200 | 158 | 109 | 113 | 112 |
| Other Income | -336 | 82 | 328 | 459 | -200 |
| Pre-tax Income | -4,341 | -11,222 | -11,138 | -11,091 | -8,719 |
| Income Tax | 3 | 0 | 5 | 10 | N/A |
| Net Income Continuous | -4,344 | -11,222 | -11,143 | -11,101 | -8,719 |
| Net Income | $-4,344 | $-11,222 | $-11,143 | $-11,101 | $-8,719 |
| EPS Basic Total Ops | -6.00 | -13.74 | -13.88 | -14.98 | -13.40 |
| EPS Basic Continuous Ops | -5.42 | -14.03 | -13.91 | -15.01 | -13.40 |
| EPS Diluted Total Ops | -6.00 | -13.74 | -13.88 | -14.98 | -13.40 |
| EPS Diluted Continuous Ops | -5.42 | -14.03 | -13.91 | -15.01 | -13.40 |
| EBITDA(a) | $-3,688 | $-11,079 | $-11,300 | $-11,379 | $-8,349 |